Can We Do It Better: Managing Atrial Fibrillation in Patients with Structural Heart Disease

Primary Audience:

cardiologists; electrophysiologists; and primary care providers


Activity Information

Credits: 0.5 AMA PRA Category 1 Credit(s)
Launch Date: November 08, 2018
Expiration Date: November 08, 2019


Bruce S. Stambler, M.D.
Director of Cardiac Arrhythmia Research and Education
Piedmont Heart Institute
Atlanta, GA

Peter R. Kowey, MD, FACC
Professor of Medicine and Clinical Pharmacology
Jefferson Medical College
Chief, Division of Cardiovascular Diseases
Main Line Health System
The William Wikoff Smith Chair in Cardiovascular Research
Lankenau Hospital and Medical Research Center
Wynnewood, Pennsylvania

Ty J. Gluckman, MD, FACC, FAHA
Medical Director, Clinical Excellence
Providence Heart and Vascular Institute, Oregon Region
Portland, Oregon


  1. Assess the clinical, economic, and quality-of-life impact of atrial fibrillation (AF).     
  2. Outline the benefits and risks of rate, rhythm, and ablation strategies for the management of AF.
  3. Review the safety, efficacy, and strategies for selection of antiarrhythmic therapy for AF.     
  4. Select appropriate AF patients for rate, rhythm, or ablation therapy in accordance with current guideline recommendations to optimize outcomes.


This activity was launched on November 8, 2018 and will expire on November 8, 2019.
This activity has been designed to meet the educational needs of cardiologists, electrophysiologists, primary care providers (MDs/DOs), nurse practitioners (NPs) and physician assistants (PAs) who practice in a primary care setting and other health care professionals involved in the care of patients with atrial fibrillation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

Horizon CME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.5 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.

Read the learning objectives and faculty disclosures.
Participate in the activity.
Complete the post-test and activity evaluation.
Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with an 75% or higher on the post-test to receive credit for this activity.
All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
Name of Faculty     
Bruce Stambler, MD        

Reported Financial Relationship    
Dr. Stambler does not have any financial relationships with any entity marketing, selling, or producing health care goods or services.

Name of Faculty
Peter Kowey, MD        

Reported Financial Relationship    
Dr. Kowey has served as a consultant for Boehringer Ingelheim, Johnson & Johnson, Sanofi and Pfizer.   
Ty Gluckman, MD, FACC, FAHA provided external review for this activity.  Dr. Gluckman discloses no relevant financial relationships with an ACCME/ANCC-defined commercial interest during the past 12 months.
Additional non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Sanofi US

Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.        

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above